Full Year 2024 Tissue Regenix Group PLC Earnings Call Transcript
Key Points
- Tissue Regenix Group PLC (LSE:TRX) reported a 9% increase in group revenues for 2024, driven by a 23% growth in the dCELL business.
- The company achieved a record adjusted EBITDA, up over 150% from the previous year, and reported its first-ever annual operating profit.
- Tissue Regenix expanded its market presence by initiating sales into the European Union and extending its relationship with Arthrex, a major sports medicine company.
- The company successfully purchased its facility in San Antonio, which is expected to support future growth and capacity expansion.
- Tissue Regenix received EU MDR and UK MDR certifications for its OrthoPure XT product, enhancing its regulatory compliance and market opportunities.
- The BioRinse division faced headwinds, with growth slowing to 4%, impacting overall revenue growth.
- The strategic review process was prolonged, monopolizing resources and delaying the release of 2024 results, which affected investor confidence.
- Inventory levels increased significantly due to regulatory delays affecting market openings, leading to challenges in inventory management.
- The company's share price fell and was not reflective of its value, complicating potential strategic transactions.
- Regulatory delays, both domestic and international, hindered the company's ability to export or import tissue products, affecting market expansion efforts.
Good afternoon, and welcome to the Tissue Regenix Group plc Final Results Investor Presentation. (Operator Instructions) Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Daniel Lee. Good afternoon to you.
Good afternoon, and good afternoon to all of the attendees. Thank you for giving us the opportunity to update you on the progress we have made at Tissue Regenix. We released our 2024 results. So we'll be spending the next hour not only presenting -- discussing the company, our activities, the accomplishments we made in 2024 and our plans for the future. But then at the end, of course, we will take -- have time to answer questions from the audience. This is the disclaimer slide, which should be reviewed by all.
Presenting today are myself and David Cocke. I'm Daniel Lee. I was appointed the Chief Officer for the Tissue Regenix Group in November of 2020. I originally joined the Tissue Regenix Group as the President
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
